英国的Nice计划发布Abbott公司的Reductil应用
LONDON (Reuters Health) - Britain's National Institute for Clinical Excellence will issue guidance on Wednesday on the use of Abbott's anti-obesity drug Reductil/Meridia (sibutramine), the cost-effectiveness watchdog said on Monday.
A positive recommendation is thought likely. NICE has already recommended, within limits, use of Roche's more expensive rival product Xenical (orlistat), which has been available in Britain since September 1998. Abbott began marketing Knoll's Reductil in the UK in May this year.
The National Health Service price for 28 days of treatment with Reductil is ?5 for a 10-mg dose and ?9.09 for a 15 mg-dose, compared with ?1.16 for Xenical.
NICE recommended Xenical in March of this year, but insisted that use of the product be limited to adults aged up to 75 years who have lost at least 2.5 kilograms by dieting in the month before starting therapy.
In addition, patients should be overweight, with a body mass index (BMI) of 28 or more and have another serious illness such as type 2 diabetes, high blood pressure or high cholesterol, or be obese with a BMI of 30. Therapy should only continue for more than 3 months if patients lose at least 5% of their body weight, and only continue for more than 6 months if they lose at least 10%.
Treatment with Xenical should not normally continue beyond 12 months and never beyond 24 months, NICE added in its guidance to the National Health Service., 百拇医药
A positive recommendation is thought likely. NICE has already recommended, within limits, use of Roche's more expensive rival product Xenical (orlistat), which has been available in Britain since September 1998. Abbott began marketing Knoll's Reductil in the UK in May this year.
The National Health Service price for 28 days of treatment with Reductil is ?5 for a 10-mg dose and ?9.09 for a 15 mg-dose, compared with ?1.16 for Xenical.
NICE recommended Xenical in March of this year, but insisted that use of the product be limited to adults aged up to 75 years who have lost at least 2.5 kilograms by dieting in the month before starting therapy.
In addition, patients should be overweight, with a body mass index (BMI) of 28 or more and have another serious illness such as type 2 diabetes, high blood pressure or high cholesterol, or be obese with a BMI of 30. Therapy should only continue for more than 3 months if patients lose at least 5% of their body weight, and only continue for more than 6 months if they lose at least 10%.
Treatment with Xenical should not normally continue beyond 12 months and never beyond 24 months, NICE added in its guidance to the National Health Service., 百拇医药